OBJECTIVE:To probe into the clinical efficacy of pemetrexed combined with cisplatin as first-line chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer.METHODS: 68 patients with advanced non-small cell lung cancer undergoing chemotherapy admitted from Jan.2010 to Dec.2015 were selected to be divided into observation group and control group via the throwing dice method, with 34 cases in each.The observation group were treated with pemetrexed combined with cisplatin, while the control group were given cisplatin combined with docetaxel, the efficacy, 1, 3 and 5 year survival rate, changes of tumor size and safety of two groups were observed.RESULTS:The total control of observation group was 79.41%(27/34), significantly higher than that of control group 52.94%(18/34), with statistically significant difference(P<0.05).The 5 year survival rate of observation group was 41.18%(14/34), significantly higher than that of control group 17.65%(6/34), with statistically significant difference(P<0.05).There were 7 cases(20.59%) with increase of the tumor size in observation group, while in control group was 16 cases(47.06%), with statistically significant difference ( P <0.05 ) .The incidence of bone marrow inhibit and liver function damage of observation group were lower than those of control group, with statistically significant difference ( P <0.05 ). CONCLUSIONS:The efficacy of pemetrexed combined with cisplatin in treatment of elderly patients with advanced non-small cell lung cancer is significant, with high safety, which is worthy of application in clinic.%目的：探讨培美曲塞联合顺铂一线化疗治疗老年非小细胞肺癌中晚期的临床疗效。方法：选择2010年1月—2015年12月接受化疗的68例老年非小细胞肺癌患者，按照抓阄法分成观察组与对照组各34例。观察组患者应用培美曲塞联合顺铂进行治疗，对照组应用顺铂联合多烯紫杉醇进行治疗，观察2组患者的疗效，1、3、5年生存率，肿瘤大小变化情况及安全性。结果：观察组患者的总控制率为79.41（27／34），明显高于对照组的52.94％（18／34），差异有统计学意义（P＜0.05）；观察组患者的5年生存率为41.18％（14／34），明显高于对照组的17.65％（6／34），差异有统计学意义（P＜0.05）；观察组7例（20.59％）患者出现肿瘤增大，对照组16例（47.06％），2组的差异有统计学意义（P＜0.05）；观察组患者骨髓抑制、肝功能损害发生率均低于对照组，差异有统计学意义（ P＜0.05）。结论：培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌疗效较好，安全性较高，值得应用于临床。
展开▼
